Core Points - Quantum Critical Metals Corp. has closed the first tranche of its non-brokered private placement financing, raising gross proceeds of $1,029,100 through the sale of 10,291,000 units at a price of $0.10 per unit [1] - Each unit consists of one common share and one common share purchase warrant, with warrants allowing the purchase of shares at $0.20 until June 27, 2027 [1] - The net proceeds will be used for exploration activities in British Columbia and Quebec, as well as for general corporate purposes [2] Group 1 - The closing of the offering is subject to final approval from the TSX Venture Exchange and other customary conditions [3] - A second and final tranche is expected to close around July 13, 2024, with securities issued subject to a four-month hold period expiring on October 28, 2025 [3] - Finder's fees included $42,387 in cash and 422,870 broker warrants for subscriptions introduced by certain persons [4] Group 2 - Certain insiders participated in this tranche, making it a "related party transaction" under Multilateral Instrument 61-101, exempt from formal valuation and minority shareholder approval [5] - Insiders contributed $100,000 in the first tranche through the issuance of 1,000,000 units [5] Group 3 - The company has a diverse portfolio of assets, including projects in gallium, rubidium, cesium, antimony, copper, and germanium, positioning it to support the transition to a sustainable critical minerals supply [8]

Core Viewpoint - Quantum BioPharma Ltd. is completing a non-brokered private placement of class A multiple voting shares at a price of $50 per share, aiming for gross proceeds of up to $600 million, expected to be fully subscribed by existing holders of MVS [1][3]. Group 1: Offering Details - The Offering consists of class A multiple voting shares priced at $50 each, with total gross proceeds anticipated to reach $600 million [1]. - All securities issued in the Offering are subject to a statutory hold period of four months plus a day from issuance, in accordance with Canadian securities laws [2]. - The proceeds from the Offering will be utilized for general working capital purposes [2]. Group 2: Insider Participation - The Offering is expected to be fully subscribed by Xorax Family Trust and Fortius Research and Trading Corp., both of which have insider connections to the Company [3]. - The participation of these insiders is classified as a "related-party transaction" under Multilateral Instrument 61-101, with exemptions from formal valuation and minority shareholder approval requirements being relied upon [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [6]. - The Company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% on sales until reaching $250 million, after which the royalty rate will decrease to 3% [6].

Core Viewpoint - Titan Pharmaceuticals, Inc. has completed a private placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management for a total of $600,000, with a conversion price set at $3.40 [1] Group 1: Private Placement Details - Blue Harbour purchased 60,000 shares of Preferred Stock for an aggregate purchase price of $600,000 [1] - The shares have a conversion price of $3.40 [1] - The transaction does not involve a public offering and has not been registered under the Securities Act of 1933 [3] Group 2: Ownership and Conversion Restrictions - The Certificate of Designations includes a beneficial ownership conversion "blocker" preventing Blue Harbour from acquiring more than 19.99% of the Company's outstanding common stock without shareholder approval [2] Group 3: Advisory and Agreements - ARC Group Ltd. served as the sole financial advisor to Titan in this private placement [4] - Titan and Blue Harbour have entered into a Registration Rights Agreement, which provides certain registration rights under specified conditions [3]

Core Viewpoint - Critical One Energy Inc. has successfully closed a non-brokered financing, raising CDN$1,000,000 through the issuance of 2,500,000 units at CDN$0.40 per unit, which will be utilized for exploration activities and general expenses [1][4]. Financing Details - The financing involved the issuance of units, each consisting of one common share and one-half common share purchase warrant, with full warrants allowing the purchase of one common share at CDN$0.60 for 18 months [2]. - A director participated in the financing, acquiring 230,000 units for a total of CDN$92,000, qualifying as a related party transaction [2][3]. Regulatory Compliance - The company relied on exemptions from valuation and minority approval requirements under Multilateral Instrument 61-101, as the transaction did not exceed 25% of the company's market capitalization [3]. Use of Proceeds - Proceeds from the private placement are earmarked for exploration activities at the Howells Lake Antimony Gold Project and for general administrative expenses [4]. Company Overview - Critical One Energy Inc. focuses on critical minerals and upstream energy, with a strategic position to meet the rising global demand for critical minerals, particularly through its antimony-gold exploration in Canada and uranium interests in Namibia [5].

Core Viewpoint - XORTX Therapeutics Inc. is conducting a non-brokered private placement to raise up to USD $925,000 through the issuance of common share units, aimed at advancing its programs for gout and progressive kidney disease [1][5]. Group 1: Offering Details - The private placement will involve the issuance of up to 1,267,123 common share units at a price of USD $0.73 per unit, each unit consisting of one common share and one common share purchase warrant [1]. - Each warrant will allow the holder to purchase an additional common share at USD $1.20, valid for 60 months from the closing date, with an acceleration clause if the common shares exceed USD $2.00 for 10 consecutive trading days [1]. Group 2: Regulatory Compliance - The offering will be available to purchasers in Canada, excluding Quebec, under the Listed Issuer Financing Exemption, meaning the securities will not be subject to a hold period under Canadian securities laws [2]. - The offering document related to the placement can be accessed on the company's profile and website, and prospective investors are encouraged to review it before making investment decisions [3]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized to advance XORTX's programs for gout and for general corporate purposes [5]. Group 4: Company Overview - XORTX Therapeutics Inc. is focused on developing innovative therapies for gout and progressive kidney disease, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [6]. - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [6].

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- Mustang Energy Corp. (CSE: MEC, OTC: MECPF, FRA: 92T) (“Mustang” or the “Company”) is pleased to announce a non-brokered private placement (the “Offering”) for aggregate gross proceeds of up to C$3,000,000 from the sale of any combination of the following: non-flow through units of the Company (each, a “Unit”) at a price of C$0.14 per Unit;critical ...

Core Points - Fitzroy Minerals Inc. plans to complete a non-brokered listed issuer financing exemption (LIFE) private placement, aiming to raise up to $12 million at a price of $0.30 per share, with a minimum offering amount of $8 million [1][2] - The company will also conduct a concurrent non-brokered private placement of up to $1 million through the issuance of up to 3,333,333 shares at the same price [3] - Proceeds from the private placements will be allocated for exploration activities, property commitments, general administrative costs, and working capital [4] Regulatory and Offering Details - The LIFE Offering is conducted under National Instrument 45-106 and will not have a hold period under Canadian securities laws [2] - Securities from the concurrent offering will be subject to a statutory hold period of four months and one day [3] - The closing of the private placements is expected around July 5, 2025, pending TSXV approval [5] Insider Participation - Insiders of the company are expected to participate in the concurrent offering, which may be considered a related party transaction but will be exempt from certain formal requirements [6] Company Overview - Fitzroy Minerals focuses on exploring and developing mineral assets in the Americas, with projects including Buen Retiro and Caballos in Chile, Taquetren in Argentina, and Cariboo in Canada [9]

Core Viewpoint - Cyclacel Pharmaceuticals has successfully completed a private placement of its convertible Series F Preferred Stock, raising gross proceeds of $3.0 million, which will be utilized for working capital and general corporate purposes [1][2]. Group 1: Financing Details - The private placement involved the issuance of convertible Series F Preferred Stock and warrants to purchase a total of 9,810,000 shares of common stock at varying exercise prices of $0.51, $0.60, and $0.68 per share [1]. - The offering closed on June 20, 2025, and the warrants will expire five years from the date of issuance [1]. - Each share of Preferred Stock is convertible into 3.27 shares of Common Stock, subject to stockholder approval as per Nasdaq listing rules [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes, which, along with existing cash, is expected to extend the company's cash runway into the third quarter of 2025 [2]. Group 3: Regulatory and Legal Aspects - The securities issued in the private placement have not been registered under the Securities Act of 1933 and were sold in reliance on Regulation S [4]. - The offering was conducted directly to investors without the involvement of a placement agent, underwriter, broker, or dealer [4]. Group 4: Company Overview - Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines, particularly through its anti-mitotic program, plogosertib, which targets PLK1 in various cancer types [7].

Core Viewpoint - Talon Metals Corp. has successfully closed a total financing of $41 million through a brokered private placement and a concurrent non-brokered private placement to advance its Tamarack Nickel Project and for general corporate purposes [1][2][5]. Group 1: Financing Details - The brokered private placement (LIFE Offering) raised gross proceeds of $25.3 million by issuing 115,000,000 units at a price of $0.22 per unit [1]. - The non-brokered private placement (Non-LIFE Offering) generated gross proceeds of $15.69 million through the issuance of 71,318,184 units at the same offering price [2]. - The total financing amount of $41 million consists of both the LIFE and Non-LIFE offerings [1][2]. Group 2: Unit Structure and Warrant Details - Each LIFE Unit and Non-LIFE Unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at $0.28 for 36 months [4]. - If the closing price of common shares exceeds $0.56 for 20 consecutive trading days, the company may accelerate the expiry date of the warrants [4]. Group 3: Use of Proceeds - The net proceeds from the offerings will be utilized to advance the Tamarack Nickel Project, as well as for general administrative expenses and working capital [5]. Group 4: Participation and Related Party Transactions - Certain directors and affiliates of Pallinghurst Nickel International Ltd. participated in the Non-LIFE Offering, acquiring 6,222,728 units for approximately $1.37 million [3][7]. - Following this acquisition, these parties hold about 0.55% of the issued and outstanding common shares on a non-diluted basis [8]. Group 5: Company Overview - Talon Metals Corp. is a base metals company listed on the TSX, engaged in a joint venture with Rio Tinto on the Tamarack Nickel-Copper-Cobalt Project in Minnesota [10]. - The company currently owns 51% of the Tamarack Nickel Project and has plans to expand its high-grade nickel mineralization resource [10]. - Talon has received significant funding from the US Department of Energy and the US Department of Defense to support its exploration efforts [10].

Core Points - Sienna Resources Inc. has successfully closed a non-brokered private placement under the Listed Issuer Financing Exemption, raising gross proceeds of $499,957.50 by selling 4,761,500 units at a price of $0.105 per unit [1] - Each unit consists of one common share and one transferable share purchase warrant, which can be exercised at a price of $0.14 for a period of 60 months [1] - The net proceeds will be allocated for general working capital and to fund exploration and development activities on existing projects [2] Financial Details - The company paid a cash finder's fee of $10,080.53 and issued 96,005 non-transferable finder's warrants, each exercisable at $0.14 for 24 months [2] - The financing is expected to provide the company with the necessary resources to initiate fieldwork and exploration activities during the summer [4] Project Focus - Sienna's immediate priority is the Stonesthrow Gold Project in Saskatchewan, covering approximately 31,718 contiguous acres [3] - The company is also evaluating its Case Lake lithium project in Ontario and its lithium assets in Nevada [3] Management Commentary - Jason Gigliotti, President of Sienna, emphasized the potential of the Stonesthrow Gold Project due to its strategic location and scale, indicating a phase of growth focused on active exploration and value creation [4]